Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets

• Published in: JTO clinical and research reports Vol. 5; no. 2; p. 100623
• Main Authors: Zhang, Bingnan, Lewis, Whitney, Stewart, C. Allison, Morris, Benjamin B., Solis, Luisa M., Serrano, Alejandra, Xi, Yuanxin, Wang, Qi, Lopez, Elyse R., Concannon, Kyle, Heeke, Simon, Tang, Ximing, Raso, Gabriela, Cardnell, Robert J., Vokes, Natalie, Blumenschein, George, Elamin, Yasir, Fosella, Frank, Tsao, Anne, Skoulidis, Ferdinandos, Hume, Celyne Bueno, Sasak, Koji, Lewis, Jeff, Rinsurongkawong, Waree, Rinsurongkawong, Vadeerat, Lee, Jack, Tran, Hai, Zhang, Jianjun, Gibbons, Don, Vaporciyan, Ara, Wang, Jing, Park, Keunchil, Heymach, John V., Byers, Lauren A., Gay, Carl M., Le, Xiuning
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2024; Elsevier
• Subjects: Brief Report; Cell surface target; Histologic transformation; NSCLC; Osimertinib; Resistance mechanism; SCLC; SCLC; Osimertinib; Histologic transformation; NSCLC; Cell surface target; Resistance mechanism

NSCLC transformation to SCLC has been best characterized with EGFR-mutant NSCLC, with emerging case reports seen in ALK, RET, and KRAS-altered NSCLC. Previous reports revealed transformed SCLC from EGFR-mutant NSCLC portends very poor prognosis and lack effective treatment. Genomic analyses revealed...